Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease submitted to different types of treatment: 10-year follow-up of the MASS II study

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLIMA, E. G.
dc.contributor.authorHUEB, W.
dc.contributor.authorRAHMI, R.
dc.contributor.authorVIEIRA, R. D. O.
dc.contributor.authorGARZILLO, C. L.
dc.contributor.authorPEREIRA, A. C.
dc.contributor.authorHUEB, A. C.
dc.contributor.authorREZENDE, P. C.
dc.contributor.authorRAMIRES, J. A. F.
dc.contributor.authorKALIL FILHO, R.
dc.contributor.groupauthorMASS II Trial
dc.date.accessioned2013-10-11T21:17:41Z
dc.date.available2013-10-11T21:17:41Z
dc.date.issued2012
dc.description.abstractPurpose: Metabolic syndrome (MetS) is understood as a condition that promotes atherosclerosis and confers an additional risk of adverse cardiovascular eventsin patients with coronary artery disease. The prognosis of this syndrome in this subset of patients in a long term follow up is inconclusive. Evaluate the impact of metabolic syndrome on cardiac death in patients with symptomatic chronic multivessel coronary artery disease. Methods: Patients randomized in MASS II study submitted to coronary artery bypass graft (CABG),angioplasty (PCI) or medical treatment (MT) were evaluated for the presence of MetS and followed prospectively for 10 years. We evaluated the incidence of overall and cardiac death in this period. Results: Criteria for MetS were fulfilled in 283 patients of 583 (54%) randomized to three therapeutic strategies. The presence of MetS was associated with an increased cardiac related death in studied population. During a 10-year follow- up, the probability cardiac mortality free survival was significantly different among patients in the 2 groups (MetS = 81,6% x non-MetS = 91,3% P=0.004). Stratifying patients with MetS by therapeutic approach we identify a statistical difference in cardiac death free survival comparing interventional approaches (CABG and PCI) to MT: 82,4% for CABG; 86,2% for PCI and 75,9% for MT(P=0,003). Besides, there is a group with best prognosis: patients without MetS submitted to CABG presenting 98,7% of patients free of cardiac death in a 10-year follow-up. Conclusion: MetS confers high rates of cardiac death in patients with stable coronary artery disease irrespective of therapeutic strategy used. In patients with MetS, interventional approaches (PCI or CABG) seem to confer more protection against cardiac death in a 10-year follow-up.
dc.description.conferencedateAUG 25-29, 2012
dc.description.conferencelocalMunchen, GERMANY
dc.description.conferencenameCongress of the European-Society-of-Cardiology (ESC)
dc.description.indexMEDLINE
dc.identifier.citationEUROPEAN HEART JOURNAL, v.33, suppl.1, p.780-780, 2012
dc.identifier.issn0195-668X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2777
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofEuropean Heart Journal
dc.rightsrestrictedAccess
dc.rights.holderCopyright OXFORD UNIV PRESS
dc.subject.wosCardiac & Cardiovascular Systems
dc.titleImpact of metabolic syndrome on the outcome of patients with stable coronary artery disease submitted to different types of treatment: 10-year follow-up of the MASS II study
dc.typeconferenceObject
dc.type.categorymeeting abstract
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.contributor.author-fmusphcEDUARDO GOMES LIMA
hcfmusp.contributor.author-fmusphcWHADY ARMINDO HUEB
hcfmusp.contributor.author-fmusphcROSA MARIA RAHMI GARCIA
hcfmusp.contributor.author-fmusphcRICARDO D'OLIVEIRA VIEIRA
hcfmusp.contributor.author-fmusphcCIBELE LARROSA GARZILLO
hcfmusp.contributor.author-fmusphcALEXANDRE DA COSTA PEREIRA
hcfmusp.contributor.author-fmusphcALEXANDRE CIAPPINA HUEB
hcfmusp.contributor.author-fmusphcPAULO CURY REZENDE
hcfmusp.contributor.author-fmusphcJOSE ANTONIO FRANCHINI RAMIRES
hcfmusp.contributor.author-fmusphcROBERTO KALIL FILHO
hcfmusp.description.beginpage780
hcfmusp.description.endpage780
hcfmusp.description.issuesuppl 1
hcfmusp.description.volume33
hcfmusp.origemWOS
hcfmusp.origem.wosWOS:000308012405478
hcfmusp.publisher.cityOXFORD
hcfmusp.publisher.countryENGLAND
relation.isAuthorOfPublicationa354095f-ee4d-48b4-8684-c6cdfa32b731
relation.isAuthorOfPublication60b53bfd-695d-4a77-a444-de58fb0bada0
relation.isAuthorOfPublication7406ddf8-9529-4c1c-b2d0-e1efe1605efa
relation.isAuthorOfPublication1464147e-29f8-4b02-bda2-a669740353c9
relation.isAuthorOfPublicationfa91ff34-659d-496b-8026-4b56f389967e
relation.isAuthorOfPublication415ce7ca-65c1-4699-b6f4-19dae8b03849
relation.isAuthorOfPublicationa8c5815f-c258-410e-adbf-34b2cd1136a7
relation.isAuthorOfPublication88850f7d-56cd-4ba5-b2d4-b824b64b15c4
relation.isAuthorOfPublicationf5d62c04-a7ad-4984-95b7-4b603eceb3da
relation.isAuthorOfPublicationc934e4bf-7bb3-4e4d-aaac-07d8be41a3ac
relation.isAuthorOfPublication.latestForDiscoverya354095f-ee4d-48b4-8684-c6cdfa32b731
Arquivos
Coleções
Comunicações em Eventos - FM/MCP
Comunicações em Eventos - HC/InCor
Comunicações em Eventos - LIM/11
Comunicações em Eventos - LIM/13